BOCA RATON, Fla., Nov. 16, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in two upcoming investor conferences:
For more information and registration, please visit the conference websites: Evercore ISI and Drexel Hamilton.
About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Investor Relations:Jeffrey Goldberger / Allison Soss KCSA Strategic CommunicationsPhone: 212-896-1249 / 212-896-1267Email: [email protected] / [email protected]
Advertisement
- Evercore ISI MedTools Investor Conference to be held at the Boston Harbor Hotel in Boston, MA on Wednesday, November 30, 2016.
- Drexel Hamilton's Emerging Growth Conference to be held at the Drexel Hamilton Offices, 77 Water Street in New York, NY on Thursday, December 1, 2016. Joe Sardano will present at 1:30pm ET. The presentation will be available via live audio webcast and archived replay on Sensus' investor relations website at investors.sensushealthcare.com/events-and-presentations.
Advertisement
For more information and registration, please visit the conference websites: Evercore ISI and Drexel Hamilton.
About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Investor Relations:Jeffrey Goldberger / Allison Soss KCSA Strategic CommunicationsPhone: 212-896-1249 / 212-896-1267Email: [email protected] / [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-two-upcoming-investor-conferences-on-november-30th-and-december-1st-300363952.html
SOURCE Sensus Healthcare
